【藥品訊息】 Forteo 筆針 衛教單張

Postmenopausal osteoporosis, Primary or hypogonadal osteoporosis

Teriparatide contains recombinant human parathyroid hormone. The pharmacologic activity of teriparatide is similar to the physiologic activity of PTH, stimulating osteoblast function, increasing gastrointestinal calcium absorption, increasing renal tubular reabsorption of calcium. Teriparatide increases bone mineral density, bone mass, and strength. Teriparatide

Bioavailability: 95%; Metabolism: Hepatic (nonspecific proteolysis); Excretion: Urine (as metabolites); Elimination Half-life: Serum: I.V.: 5 min; SubQ: 1 hour

patients with hypersensitivity to teriparatide or any component of the formulation.

Warnings
1. Osteosarcoma:
Avoid use in patients with an increased risk of osteosarcoma (including Paget disease, bone metastases or a history of skeletal malignancies, prior external beam or implant radiation therapy involving the skeleton, hereditary disorders predisposing to osteosarcoma, or in patients with open epiphyses).
2. Hypercalcemia:
Use with caution in patients with hypercalcemia (not studied); may increase or exacerbate hypercalcemia. Avoid use in patients with known or history of hypercalcemia disorder (eg, primary hyperparathyroidism)
3. Cutaneous calcification:
Serious worsening of previous stable cutaneous calcification or calciphylaxis has been reported; discontinue use if occurs. Patients with underlying autoimmune disease, kidney failure, or concomitantly taking warfarin or systemic corticosteroids are at increased risk.
#仿單變更2022

C [FDA]; Teriparatide is not indicated for use in pregnant or premenopausal women.

Excretion in breast milk unknown/not recommended

Hypotension, syncope, asthenia, nausea, dizziness, rhinitis, hyperuricemia, injection site reactions (bleeding, bruising, erythema, pain, pruritus, swelling)

20 mcg once a day; should be administered as a subcutaneous injection into the thigh or abdominal wall.
Initial administration should occur under circumstances in which the patient may sit or lie down, in the event of orthostasis.

Store at 2-8℃ at all times. Each teriparatide pen can be used for up to 28 days after the first injection.